CytoDyn Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal Cancer
VANCOUVER, Washington, Aug. 12, 2024 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB:CYDY) (“CytoDyn” or the “Company”), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that it completed a meeting with the U.S. Food and Drug Administration (FDA) to gain alignment on the rationale and proposed dosing for the Company’s Phase II study that will investigate the preliminary safety and activity of leronlimab in combination with trifluridine plus tipiracil (TAS-102) and bevacizumab in participants with CCR5+, microsatellite stable (MSS), relapsed or refractory metastatic colorectal cancer (mCRC).
Related news for (CYDY)
- CytoDyn Releases ESMO Breast Cancer Meeting Poster
- CytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid Tumors
- CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer
- CytoDyn Leadership Team To Attend ESMO Breast Cancer Meeting in Munich, Germany
- CytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with Leronlimab